Xilio Therapeutics Inc (XLO) Share Price

Your up good on STAI in after-mkt,is it Tuesday yet

Followed you to STAI. Like you I got in at 2. Looks good. Sold XLO at 1.2 for a small loss but still keeping an eye on it

Nice find

Found a freely trading ticker to show you what a freely traded looks like,STAI,3.69m float,1m short,no convertible/dilutive or even variable rate debt! Trading freely!!!

Too risky for me,gap fill back to .60s is what I will wait for,meanwhile 10,000 other tickers to choose from (some with no manipulation and less risk)

Darkpool/mms(banks/inst.)have unlimited shares. They sold millions of shares they didn’t own. The new laws were designed to make markets flow without having to wait for a buyer and seller to exchange directly,worked great until banks/mms abused it and are not held accountable to complete the transaction before the next trading session. Just allowed to steal whatever they want from retail

Manipulation. I almost bought more at 1.08 and now I wish I had. My initial and only buy at this point is 1.27 so I'm not hurt too bad. If I had bought at 1.08 I'd be about even now.

This should have been the greatest trade of the year,instead it’s my biggest loss in 10 years

Ikr,cents less(pun intended) at least last time it traded a pennant for 2 weeks before dropping,this time they shit all over it,about $200m traded and it barely doubled.
Many ppl took huge loss and won’t go back because of wash sale tax write off,big mistake on XLO to destroy retail but they don’t care,to them it’s all about institutional (inst. control 90% of mkt,so please them not retail)

Float is only 22.7 million shares

Doesn't make sense they would drain the stock after getting 50M??

Unfortunately co. Is destroying this atm,like last time 28th March deal with Gilliad,same 50m upfront and 10m stock at premium.and they diluted every buy until ppl gave up and sold.
we should have hit $6.00 with all that buying volume this time,I will be watching if they stop diluting and let it run free

The deal they signed gives them 52M up front. That alone make this stock worth at least $1 up from previous price, so $1.66 a share not to mention the 2.1B in additional contingent payments.

Many institutions increased or added positions yesterday,held down to get cheap.i see Morgan Stanley holds a large position and Giliad has over 10% (added more in dec on top of the 10m from last March deal

Feels like algo rythyms running this today.....sells that could easily have been made at higher amounts and everytime a candle buy pattern develops; it immediately gets shut down. Will hang on to my shares until true value is reached. (not sure what that is, but it looks to me like at least a dollar higher than we are right now)

ZERO BORROW again,68%fee(no rebate this time is key!!) bear trap set to kill now!

Bought 10k more 1.31,death hr over in 15min,could pop any min

Shares to short started again,trap didn’t hold,maybe $1 support

Gaps usually fill,rarely don’t fill,confidence strong enough,will know by 10:30-11

New buy rating $5.00 from reputable investors (not scam pumpers hc wainwright)

AbbVee buying $10m shares @ $2.30 premium ,not sure when

Zero borrow now,bear trap snapped shut,got them caught,will see if it holds.

Biotechnology Financial Analyst positive
This collaboration marks a transformative moment for Xilio Therapeutics, significantly strengthening its financial position and validating its tumor-activated biologics platform. The deal's structure is particularly noteworthy: the $52 million upfront payment, including a $10 million equity stake, provides immediate capital injection, while the $2.1 billion in potential milestone payments creates substantial long-term value potential.

The equity investment component is especially significant as it demonstrates AbbVie's strong commitment and confidence in Xilio's technology. This strategic alignment with a major pharmaceutical player provides Xilio with not just financial resources but also access to AbbVie's extensive oncology development expertise and commercial infrastructure.

The focus on masked T-cell engagers represents a cutting-edge approach in immuno-oncology. Traditional immunotherapies often face challenges with systemic toxicity, limiting their therapeutic window. Xilio's tumor-selective activation technology addresses this critical limitation by concentrating therapeutic activity within the tumor microenvironment, potentially enabling higher dosing and better efficacy while minimizing side effects.

From a financial perspective, this deal transforms Xilio's risk profile. The substantial upfront payment strengthens their balance sheet, while the milestone structure provides multiple value-creation opportunities throughout the development process. The tiered royalty structure ensures long-term value capture if products reach commercialization.

The partnership structure allows Xilio to retain significant value in their platform while leveraging AbbVie's resources for development and commercialization. This hybrid approach optimizes the risk-reward profile for both companies and potentially accelerates the development timeline for novel cancer therapeutics.

This should have crossed $2 today.

Hello EZ,thanks for alert,good to hear from you old friend! Good skill bro!

Going to be biggest bear trap in history,or great short,30k Ava.every 15m@only 4%fee
I am betting on rare bear trap,news is astronomical value increase.

$XLO 52 Million in Cash and over 2 Billion in Milestone payments with $ABBV https://www.stocktitan.net/news/XLO/abb-vie-and-xilio-therapeutics-announce-collaboration-and-option-x3e2lxgw8uc1.html

AbbVie paying,$52m,upfront payment,up to $2.1Billion royalties,up front payment alone is close to mkt cap,under value much

https://ih.advfn.com/stock-market/NASDAQ/xilio-therapeutics-XLO/stock-news/95418853/xilio-therapeutics-announces-multiple-masked-t-cel

https://ih.advfn.com/stock-market/NASDAQ/xilio-therapeutics-XLO/trades

If pattern continues,it’s time for vol surge and this could be best yet as they continue to increase

11:30 vol surge started,that’s the pattern unless it surges on hr and 1/2 hr(that’s a really strong ticker) ohh wow as I am typing it blasts up 1.66 wee haww

XLO: And there she GOES, Capt. Timmy!!! (Maybe??? Hopefully??? STRANGER things HAVE transpired on Wall Street Lane, ya know!!)

Death hour now (10:30-11:30)I don’t expect move until after 11 maybe 11:15 should start vol surges every hr if it’s strong enough

ZERO BORROW now ,fee is only 9% so I expect that to go up around 400% once shares are in more demand

Only 1k shares to short remain,ZERO BORROW coming and kaboom

Resistance is $5 $10 $15 value potential is astronomical

https://ih.advfn.com/stock-market/NASDAQ/xilio-therapeutics-XLO/stock-news/95418850/abbvie-and-xilio-therapeutics-announce-collaborati

Thank you bro for letting me know,I would have missed it.this is the news we were waiting for! Instant 10Xs value

$XLO: Now 1.40 !

Good Call.......... keep em coming



GO $XLO

$16 feasible. we shall see

XLO: One of their PR's boasted, a "POTENTIAL 2-BILLION" income for them.

$1.43 ....Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers ....

Nice move $1.38 + 110%

Running up at close is good,loaded up on chart reversal this morning

January 21, 2025 at 5:05 PM EST
PDF Version27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastasesResponses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) and improvement in clinical symptomsData continue to demonstrate differentiated safety and tolerability profile for the combination with low incidence of immune-related adverse eventsXilio Therapeutics to host investor conference call and webcast on Wednesday, January 22, 2025, at 8:30 am ETWALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced initial data from its ongoing Phase 2 clinical trial evaluating vilastobart (XTX101), a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The data will be presented in a poster session (abstract #206) at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer Symposium (ASCO GI) being held January 23-25, 2025, in San Francisco.“We are very encouraged by the initial Phase 2 proof-of-concept data for the combination of vilastobart and atezolizumab in heavily pre-treated patients with MSS colorectal cancer, including partial responses accompanied by marked decreases in tumor biomarkers and improvement in clinical symptoms,” said Katarina Luptakova, M.D., chief medical officer of Xilio. “We believe these data highlight the important contribution of vilastobart in this combination, as PD-(L)1 inhibitors alone have demonstrated no meaningful efficacy in patients with MSS CRC to date. The preliminary evidence of anti-tumor activity, together with continued evidence of a well-tolerated safety profile, support the potential for the combination in MSS colorectal cancer, as well as in other tumors that have traditionally been resistant to treatment with immunotherapy. We look forward to sharing additional Phase 2 data, including further follow-up, in patients with metastatic MSS CRC in the middle of this year.”“These preliminary Phase 2 data for the combination of vilastobart and atezolizumab show clear responses for patients with MSS colorectal cancer, an area of very high and increasing unmet medical need,” said J. Randolph Hecht, M.D., Professor of Clinical Medicine at the David Geffen School of Medicine at UCLA, Director of the UCLA Gastrointestinal Oncology Program and the lead author for the presentation at ASCO GI. “I am excited to see these initial data highlighting the potential for vilastobart, a tumor-activated anti-CTLA-4, in combination with PD-(L)1 inhibitors to have clinically meaningful benefit in a classically immunotherapy-resistant major malignancy.”Data from Phase 2 Trial for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic MSS CRCAs of a data cutoff date of January 13, 2025, 40 patients with metastatic MSS CRC had been treated with the combination of vilastobart at a dose of 100 mg once every six weeks (Q6W) and atezolizumab at 1200 mg once every three weeks (Q3W). The median age was 55 years (ranging from 25 to 82 years), and patients were heavily pre-treated, with 70% of patients having previously received three or more prior lines of anti-cancer therapy.Preliminary Anti-Tumor Activity DataIn patients without liver metastases, the preliminary objective response rate (ORR) was 27% with three partial responses (PRs), including two confirmed PRs. Responses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) as well as improvement in clinical symptoms.As of the data cutoff date, 18 patients had at least one imaging scan reported and were evaluable for response assessment (per RECIST version 1.1 criteria), including 11 patients without liver metastases and seven patients with liver metastases.In response-evaluable MSS CRC patients without liver metastases, investigators reported three PRs (two confirmed, one pending confirmation), with each patient ongoing on treatment as of the data cutoff date:PR (confirmed) with a 47% decrease in the sum of diameters of target lesions at 13 weeks accompanied by a decrease in levels of the serum tumor marker CEA, a multi-log fold decrease in levels of ctDNA and improvement of clinical symptoms, such as cough. CEA is a serum biomarker that is often elevated in many malignancies, including colorectal cancer, and ctDNA is a biomarker found in the bloodstream of patients with cancer.

PR (confirmed) that continued to deepen over time with a 57% reduction in the sum of diameters of target lesions at 18 weeks accompanied by a multi-log fold decrease in ctDNA to undetectable levels and significant decrease in levels of the serum tumor marker CEA to normal values.

PR (pending confirmation) with a 35% decrease in the sum of diameters of target lesions at nine weeks accompanied by a decrease in levels of the tumor marker CEA to normal values, a substantial decrease in levels of ctDNA and improvement of clinical symptoms, such as cough. For this patient, the initial response on CT imaging was assessed by the investigator and the radiology assessment is pending.
In addition, an MSS CRC patient without liver metastases but with a peritoneal metastasis had a 24% decrease in the sum of diameters of target lesions assessed by CT imaging at their initial nine-week scan accompanied by a decrease in levels of the serum tumor marker CEA to normal values. This patient was ongoing on treatment as of the data cutoff date.Investigators reported stable disease in three patients without liver metastases and one patient with liver metastases, representing a preliminary disease control rate of 55% and 14%, respectively, and highlighting additional evidence of anti-tumor activity for the combination.As of the data cutoff date, 23 patients were ongoing on treatment, including 13 patients who had not yet had a first response assessment.Preliminary Safety DataSafety data continue to support the potential for vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors. Consistent with the tumor-selective design for vilastobart, the combination was generally well-tolerated, with patients experiencing a low incidence of immune-related adverse events (irAEs) and only 5% of patients reporting colitis.As of the data cutoff date, 40 patients were evaluable for safety. Across all patients treated:Investigators reported only six patients with Grade 3 or 4 treatment-related adverse events (AEs), including only two Grade 4 treatment-related AEs (laboratory abnormalities of thrombocytopenia and neutropenia, one patient each), and no Grade 5 treatment-related AEs.No patients experienced a dose reduction for vilastobart due to an AE, and only three patients discontinued treatment for the combination of vilastobart and atezolizumab due to a treatment-related AE.Investigators reported minimal endocrine irAEs (5%) and limited skin irAEs (13%), and the incidence of endocrine and skin irAEs was consistent with the incidence reported for atezolizumab alone.The most common treatment-related AEs (≥10% incidence) of any grade reported by investigators were the following: fatigue (30%); diarrhea (20%); infusion-related reactions (13%, with 8% deemed related to vilastobart and 5% deemed related to atezolizumab); pyrexia (10%); aspartate aminotransferase (AST) increase (10%); and alanine aminotransferase (ALT) increase (10%).The only Grade 3 treatment-related AE with ≥5% incidence reported by investigators was colitis (5%). Non-laboratory Grade 3 treatment-related AEs (<5% incidence) consisted of the following: maculopapular rash and febrile neutropenia in one patient; lower gastrointestinal hemorrhage in one patient with thrombocytopenia; and one patient with Triple M overlap syndrome (myocarditis, myositis and myasthenia gravis).
Clinical Development Plans for VilastobartThe Phase 2 clinical trial evaluating vilastobart in combination with atezolizumab in patients with MSS CRC is currently ongoing, and Xilio expects to report updated data from the Phase 2 trial in the middle of 2025, including additional response assessments and follow-up.These initial Phase 2 proof-of-concept data demonstrate the potential for vilastobart as a combination therapy in patients with MSS CRC and a range of other tumor types, including “cold” tumors historically resistant to immunotherapy. Based on these data, Xilio plans to seek opportunities for partnering to prioritize and expand further development beyond the initial Phase 2 proof-of-concept trial in MSS CRC.In addition, Xilio continues to enroll patients in Phase 1C dose escalation and evaluate the combination of vilastobart at the 150 mg Q6W dose level and atezolizumab at 1200 mg Q3W.Investor Conference Call Information
Xilio will host a conference call and webcast tomorrow (Wednesday, January 22, 2025) at 8:30 am ET to discuss the initial Phase 2 data for the combination of vilastobart and atezolizumab. Viewers can access the webcast by using this link. Listeners who require dial-in access should register here to receive a unique PIN and information to join the call. Listeners are encouraged to join at least 15 minutes prior to the scheduled start time. The webcast will also be accessible under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation.About Vilastobart (XTX101) and the Phase 1/2 Combination Clinical TrialVilastobart is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment (TME). In 2023, Xilio entered into a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab (Tecentriq®) in a multi-center, open-label Phase 1/2 clinical trial. Xilio is currently evaluating the safety of the combination in Phase 1C dose escalation in patients with advanced solid tumors and the safety and efficacy of the combination in Phase 2 in patients with metastatic microsatellite stable colorectal cancer with and without liver metastases. Please refer to NCT04896697 on www.clinicaltrials.gov for additional details.

https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-phase-2-data-vilastobart

https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-inducement-grant-under-nasdaq-0

Here it is

Bullish pennant on continuation. Thank me later